Protocol to establish a lung adenocarcinoma immunotherapy allograft mouse model with FACS and immunofluorescence-based analysis of tumor response

Anti-PD-1/PD-L1 therapy shows long-term effects in many cancer types, but resistance and relapse remain the main limitations of this therapy. Here, we describe a protocol to evaluate the tumor response to immunotherapy in a mouse lung cancer model. The protocol includes the establishment of the lung...

Descripción completa

Detalles Bibliográficos
Autores principales: Peng, Zhengxin, Yu, Man, Lin, Jiaming, Dong, Tianqi, Zhang, Xiao, Shi, Mingjun, Qin, Min, Li, Shasha, Guo, Wencong, Zhang, Huixia, Sun, Shuguo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8209678/
https://www.ncbi.nlm.nih.gov/pubmed/34169289
http://dx.doi.org/10.1016/j.xpro.2021.100595
Descripción
Sumario:Anti-PD-1/PD-L1 therapy shows long-term effects in many cancer types, but resistance and relapse remain the main limitations of this therapy. Here, we describe a protocol to evaluate the tumor response to immunotherapy in a mouse lung cancer model. The protocol includes the establishment of the lung cancer mouse model, anti-PD-1 treatment, tumor-infiltrating lymphocyte isolation, immunofluorescence, and flow cytometry analysis. This protocol can also be applied to other cancer types and immunotherapies. For complete details on the use and execution of this protocol, please refer to Yu et al. (2021)

Ejemplares similares